AI Article Synopsis

  • Small cell carcinoma of the bladder (SCCB) is a rare and aggressive cancer, typically treated with a bladder-sparing approach combining chemotherapy and radiotherapy, though the rates of intravesical recurrence are not well understood.
  • In a study of 110 patients, 89 had limited disease; 35% progressed to distant metastasis while 22% experienced isolated intravesical recurrence, with salvage treatments achieving a 64% complete response rate.
  • Survival rates differ significantly between patients with intravesical recurrence (28 months) and those with systemic recurrence (8 months), indicating that even limited disease can quickly escalate into more serious conditions.

Article Abstract

Introduction: Small cell carcinoma of the bladder (SCCB) is a rare and lethal disease. Previously, we and others have reported a bladder sparing strategy with platinum-etoposide-based chemotherapy followed by radiotherapy of the bladder. Little is known on frequency and treatment of intravesical recurrence following this approach. The objective of this study is to describe the incidence of intravesical recurrences and their management.

Materials And Methods: Retrospective study including all patients with SCCB treated at a single institution from 1993 until 2016. All patients with limited disease (LD) SCCB who had a bladder sparing approach with sequential chemotherapy and radiotherapy were identified. Intravesical and overall recurrence rate, overall and disease specific survival, salvage treatment options and their results were retrieved.

Results: Of the 110 patients with SCCB (82% male) with a mean age of 65 years and a median follow up of 48 months, 89 patients (81%) had LD-SCCB. Of these, 65 were treated with chemotherapy and radiotherapy, with a median overall recurrence free survival of 22 months (CI: 14-30). Of 65 patients, 23 (35%) progressed to distant metastasis without intravesical recurrence after a median of 9 months (CI: 8-11), whereas 14 patients (22%) developed isolated intravesical recurrence at a median of 24 months (CI: 14-34). Local recurrence contained SCCB, urothelial carcinoma, and carcinoma in situ and was treated with various local salvage treatments including TURB, cystectomy, neoadjuvant chemotherapy, and BCG. Following salvage treatment a complete response was seen in 64%. Median overall survival for intravesical vs. systemic recurrence was different, with 28 (CI: 9-47) and 8 (CI: 5-11) months, respectively (P<0.001).

Conclusion: SCCB is a serious potentially lethal disease. Even in patients with LD-SCCB a high percentage rapidly develops systemic disease. This suggests that systemic therapy is more important than the type of local treatment to control the disease but small sample sizes limit the ability to distinguish between different treatment options in this study. A bladder sparing approach can be a reasonable alternative to major surgery. However, in those surviving long enough isolated intravesical recurrence occurs even after many years. Our results indicate that long term follow up is required because salvage therapy can be successful in the majority of patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.02.015DOI Listing

Publication Analysis

Top Keywords

intravesical recurrence
20
bladder sparing
12
chemotherapy radiotherapy
12
small cell
8
cell carcinoma
8
carcinoma bladder
8
patients sccb
8
salvage treatment
8
recurrence median
8
median months
8

Similar Publications

We examined the efficacy and adverse effects of low-dose intravesical Bacillus Calmette-Guérin (BCG) therapy in patients with non-muscle-invasive bladder cancer. Patients who underwent intravesical BCG therapy (n=176 ; 198 courses) at our hospital between April 2012 and December 2022 were enrolled. After assigning patients to either the low-dose or regular-dose (40 or 80 mg of BCG Tokyo 172 strain) groups, treatment efficacy and incidence of adverse events were compared.

View Article and Find Full Text PDF

Partial cystectomy as a surgical option for colorectal cancer patients with pathological bladder invasion: an original retrospective study.

Therap Adv Gastroenterol

January 2025

Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, 510655, Guangzhou, Guangdong, China.

Background: Limited research exists on colorectal cancer (CRC) patients with bladder invasion, with survival outcomes post-cystectomy underexplored and a debate between partial and total cystectomy ongoing.

Objective: The study aimed to evaluate the effect of pathological bladder invasion on the long-term tumour prognosis of patients with clinically diagnosed bladder invasion in CRC after cystectomy.

Design: Retrospective, cohort study.

View Article and Find Full Text PDF

PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.

World J Urol

January 2025

Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Room Be-304, 3015 GD, Rotterdam, The Netherlands.

Purpose: Up to 50% of high-risk non-muscle invasive bladder cancer (HR-NMIBC) patients fail Bacillus Calmette-Guérin (BCG) treatment, resulting in a high risk of progression and poor clinical outcomes. Biomarkers that predict outcomes after BCG are lacking. The antitumor effects of BCG are driven by a cytotoxic T cell response, which may be controlled by immune checkpoint proteins like Programmed Death Ligand 1 (PD-L1).

View Article and Find Full Text PDF

Intravesical instillation of chemotherapy has been performed to reduce the risk of intravesical recurrence of bladder cancer. However, its antitumor effect is not necessarily sufficient, which may be partially due to inadequate delivery of intravesically administered chemotherapeutic agents to bladder tumors. Ultrasound irradiation to target tissues in the presence of microbubbles is a technique to transiently enhance cell membrane permeability and achieve efficient drug delivery to the desired sites without damage to non-target areas; this technique has been used in chemotherapy, immunotherapy, gene therapy, and radiotherapy for the treatment of various cancers.

View Article and Find Full Text PDF

Bacillus Calmette-Guerin (BCG) is the current standard of care for non-muscle invasive bladder cancer (NMIBC), but recurrence is common. Additional therapeutic options are a major unmet medical need for treating unresponsive patients. Stimulator of Interferon Genes (STING) plays a central role in mounting innate and adaptive immune responses to tumor cells, and activation of STING is a promising immunotherapeutic approach.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!